# A Study of BGM0504 in Participants with Type 2 Diabetes

> **NCT06716216** · PHASE3 · RECRUITING · sponsor: **BrightGene Bio-Medical Technology Co., Ltd.** · enrollment: 537 (estimated)

## Conditions studied

- Type 2 Diabetes Mellitus (T2DM)

## Interventions

- **DRUG:** Drug: 5 mg BGM0504 Administered SC
- **DRUG:** Drug:10 mg BGM0504 Administered SC
- **DRUG:** Drug: Semaglutide Administered SC

## Key facts

- **NCT ID:** NCT06716216
- **Lead sponsor:** BrightGene Bio-Medical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-29
- **Primary completion:** 2026-03-20
- **Final completion:** 2026-11-14
- **Target enrollment:** 537 (ESTIMATED)
- **Last updated:** 2025-02-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06716216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06716216, "A Study of BGM0504 in Participants with Type 2 Diabetes". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06716216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*